Oncology Institute, Inc.TOIEarnings & Financial Report
Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.
Revenue
$98.6M
Gross Profit
N/A
Operating Profit
$-16.4M
Net Profit
$-15.5M
Gross Margin
N/A
Operating Margin
-16.6%
Net Margin
-15.7%
YoY Growth
22.9%
EPS
$-0.17
Financial Flow
Oncology Institute, Inc. Q2 2024 Financial Summary
Oncology Institute, Inc. reported revenue of $98.6M (up 22.9% YoY) for Q2 2024, with a net profit of $-15.5M (up 8.4% YoY) (-15.7% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $98.6M |
|---|---|
| Net Profit | $-15.5M |
| Gross Margin | N/A |
| Operating Margin | -16.6% |
| Report Period | Q2 2024 |
Oncology Institute, Inc. Annual Revenue by Year
Oncology Institute, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $502.7M).
| Year | Annual Revenue |
|---|---|
| 2025 | $502.7M |
| 2024 | $393.4M |
| 2023 | $324.2M |
| 2022 | $252.5M |
Oncology Institute, Inc. Quarterly Revenue & Net Profit History
Oncology Institute, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $142.0M | +41.6% | $-7.5M | -5.3% |
| Q3 2025 | $136.6M | +36.7% | $-16.5M | -12.1% |
| Q2 2025 | $119.8M | +21.5% | $-17.0M | -14.2% |
| Q1 2025 | $104.4M | +10.3% | $-19.6M | -18.8% |
| Q4 2024 | $100.3M | +16.9% | $-13.2M | -13.1% |
| Q3 2024 | $99.9M | +21.8% | $-16.1M | -16.1% |
| Q2 2024 | $98.6M | +22.9% | $-15.5M | -15.7% |
| Q1 2024 | $94.7M | +24.2% | $-19.9M | -21.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.7M | $98.6M | $99.9M | $100.3M | $104.4M | $119.8M | $136.6M | $142.0M |
| YoY Growth | 24.2% | 22.9% | 21.8% | 16.9% | 10.3% | 21.5% | 36.7% | 41.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $204.5M | $179.6M | $179.2M | $172.7M | $164.0M | $159.8M | $163.6M | $164.7M |
| Liabilities | $163.2M | $150.4M | $163.7M | $169.1M | $158.9M | $168.8M | $175.9M | $180.4M |
| Equity | $41.3M | $29.2M | $15.5M | $3.6M | $5.1M | $-9.0M | $-12.3M | $-15.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-15.9M | $-15.7M | $819000 | $4.2M | $-5.0M | $-10.2M | $-12.6M | $3.2M |